Lacosamide

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Focal Epilepsy With and Without Secondary Generalization

Conditions

Focal Epilepsy With and Without Secondary Generalization

Trial Timeline

Jul 1, 2012 → Jul 1, 2015

NCT ID

NCT01673282

About Lacosamide

Lacosamide is a pre-clinical stage product being developed by UCB for Focal Epilepsy With and Without Secondary Generalization. The current trial status is completed. This product is registered under clinical trial identifier NCT01673282. Target conditions include Focal Epilepsy With and Without Secondary Generalization.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03559673	Pre-clinical	Completed	—	—	Epilepsies, Partial
NCT04627285	Phase 3	Completed	Dec 28, 2020	Feb 12, 2025	Epilepsy
NCT02710890	Phase 2/3	Completed	May 30, 2017	Jun 28, 2019	Epilepsy
NCT02582866	Phase 3	Completed	Jan 1, 2016	Jan 1, 2020	Epilepsy
NCT02477839	Phase 3	Completed	Jun 5, 2015	May 28, 2020	Epilepsy With Partial-onset Seizures
NCT02124564	Phase 3	Completed	Apr 1, 2014	Nov 21, 2017	Epilepsy
NCT01969851	Phase 2	Completed	Feb 13, 2014	Apr 10, 2018	Epilepsy
NCT01921205	Phase 3	Completed	Aug 29, 2013	Jan 24, 2017	Epilepsy
NCT01724918	Phase 2	Terminated	May 1, 2013	Aug 1, 2016	Focal Epilepsy
NCT01832038	Phase 3	Completed	Mar 26, 2013	Jul 31, 2019	Epilepsy
NCT01673282	Pre-clinical	Completed	Jul 1, 2012	Jul 1, 2015	Focal Epilepsy With and Without Secondary Generalization
NCT01530386	Phase 1	Completed	Jan 1, 2012	Jul 1, 2012	Healthy Subjects
NCT01484977	Phase 3	Completed	Dec 1, 2011	Dec 1, 2013	Epilepsy
NCT01236001	Pre-clinical	Completed	Sep 1, 2010	Mar 1, 2012	Seizures
NCT01118962	Phase 2	Completed	Aug 1, 2010	Oct 1, 2012	Epilepsy
NCT01235403	Approved	Completed	Jun 1, 2010	Dec 1, 2011	Partial Epilepsies
NCT01118949	Phase 2	Completed	May 1, 2010	Aug 1, 2011	Epilepsy
NCT00938431	Phase 2	Completed	Nov 1, 2009	Aug 1, 2014	Epilepsy
NCT00955357	Approved	Completed	Aug 1, 2009	Aug 1, 2013	Partial Epilepsies
NCT00771927	Pre-clinical	Completed	Oct 1, 2008	Mar 1, 2012	Epilepsies, Partial

Competing Products

20 competing products in Focal Epilepsy With and Without Secondary Generalization

See all competitors

Product	Company	Stage	Hype Score
OnabotulinumtoxinA 145 UNT [Botox]	AbbVie	Approved	85
Dapagliflozin	AstraZeneca	Approved	85
Enfuvirtide + Tenofovir-Emtricitabine	Roche	Phase 2	52
CCX140-B	Amgen	Phase 2	51
PF-06730512	Pfizer	Phase 2	51
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide	Pfizer	Approved	84
VX-147	Vertex Pharmaceuticals	Phase 2	51
VX-147	Vertex Pharmaceuticals	Phase 1	32
IXP	Vertex Pharmaceuticals	Phase 1	32
fresolimumab + fresolimumab + Placebo	Sanofi	Phase 2	51
GC1008 + GC1008 + GC1008 + GC1008	Sanofi	Phase 1	32
frexalimab + brivekimig + rilzabrutinib + placebo	Sanofi	Phase 2	51
Vivaglobin	CSL	Phase 2	51
UCB0942	UCB	Phase 2	49
Levetiracetam + Carbamazepine + Lamotrigine	UCB	Approved	82
Brivaracetam + Brivaracetam	UCB	Phase 2	49
Lacosamide	UCB	Phase 2	49
UCB0942 + UCB0942 + Placebo	UCB	Phase 2	49
ARGX-117	Argenx	Phase 2	49
Empasiprubart + IVIG (Intravenous Immunoglobulin)	Argenx	Phase 3	74

Other Products from UCB

LevetiracetamApproved

Parcopa + carbidopa-levodopa (Sinemet)Approved

LevocetirizineApproved

RotigotineApproved

Levetiracetam + OxcarbazepineApproved